NervGen Pharma reported significant clinical and regulatory progress regarding NVG-291, its lead therapeutic candidate for chronic spinal cord injury. Following alignment with the U.S. Food and Drug Administration on the clinical trial design for its Phase 3 registrational study known as RESTORE, the company advanced site activations and patient screening preparations. Additionally, independent biomechanical gait analyses from earlier studies demonstrated statistically significant improvements in coordination and postural stability, supporting its mechanism for genuine neural recovery.